Kyntra Bio (KYNB) Current Assets (2014 - 2026)

Kyntra Bio has disclosed Current Assets across 13 years of filings, most recently posting $96.8 million for Q2 2026.

• In Q2 2026, Current Assets fell 40.35% year-over-year to $96.8 million; the TTM figure through Jun 2026 stood at $96.8 million (down 40.35% YoY), while the FY2025 annual figure was $99.1 million, down 49.58% from the prior year.
• Current Assets came in at $96.8 million for Q2 2026 at Kyntra Bio, down from $101.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $524.4 million in Q1 2022 to a low of $96.8 million in Q2 2026.
• Average Current Assets over 5 years is $290.0 million, with a median of $261.3 million recorded in 2024.
• Year-over-year, Current Assets gained 3.96% in 2022 and slumped 49.58% in 2025.
• Over 5 years, Current Assets stood at $492.8 million in 2022, then tumbled by 32.72% to $331.6 million in 2023, then tumbled by 40.73% to $196.5 million in 2024, then tumbled by 49.58% to $99.1 million in 2025, then declined by 2.27% to $96.8 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $96.8 million in Q2 2026, $101.4 million in Q1 2026, and $99.1 million in Q4 2025.